scispace - formally typeset
S

Shilin N. Shukla

Publications -  7
Citations -  3287

Shilin N. Shukla is an academic researcher. The author has contributed to research in topics: Cancer & Colorectal cancer. The author has an hindex of 5, co-authored 5 publications receiving 2494 citations.

Papers
More filters
Journal ArticleDOI

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

Franck Pagès, +120 more
- 26 May 2018 - 
TL;DR: The immunoscore provides a reliable estimate of the risk of recurrence in patients with colon cancer and supports the implementation of the consensus Immunoscore as a new component of a TNM-Immune classification of cancer.
Journal ArticleDOI

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.

Jérôme Galon, +56 more
TL;DR: In colorectal cancer, the Immunoscore may add to the significance of the current AJCC/UICC TNM classification, since it has been demonstrated to be a prognostic factor superior to the AJCC or UICCTNM classification.
Journal ArticleDOI

Cancer classification using the Immunoscore: a worldwide task force

Jérôme Galon, +68 more
TL;DR: Evidence supports the notion to include immunological biomarkers, implemented as a tool for the prediction of prognosis and response to therapy, into traditional classification of cancer, designated TNM-I (TNM-Immune), and introduction of this parameter as a biomarker to classify cancers will facilitate clinical decision-making.
Journal ArticleDOI

Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.

Bernhard Mlecnik, +101 more
TL;DR: It is suggested that patients with a high Immunoscore will benefit the most from chemotherapy in terms of recurrence risk, as well as the effect of chemotherapy on time to recurrence (TTR).
Journal ArticleDOI

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016

Sonja Althammer, +421 more
TL;DR: O1 Combinatorial CD8+ and PD-L1+ cell densities correlate with response and improved survival in non-small cell lung cancer patients treated with durvalumab.